Heterogeneity Amongst GLP-1 RA Cardiovascular Outcome Trials Results: Can Definition of Established Cardiovascular Disease Be the Missing Link?

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce b...

Full description

Bibliographic Details
Main Author: Melo, M (author)
Other Authors: Gavina, C (author), Silva-Nunes, J (author), Andrade, L (author), Carvalho, D (author)
Format: article
Language:eng
Published: 2021
Subjects:
HCC END
Antidiabetic Drug
GLP-1 RA
Cardiovascular Disease
Cardiovascular Outcome Trials
Type 2 Diabetes
Online Access:http://hdl.handle.net/10400.17/3779
Country:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3779

Internet

http://hdl.handle.net/10400.17/3779

Similar Items